Sonnet BioTherapeutics Holdings, Inc.

SONN · NASDAQ
Analyze with AI
9/30/2025
9/30/2024
9/30/2023
9/30/2022
Market Cap$4,384$2,974$6,385
- Cash$5,120$149$2,274$3,053
+ Debt$0$131$204$256
Enterprise Value$4,365$904$3,588
Revenue$1,000$19$148$350
% Growth5,268.8%-87.4%-57.8%
Gross Profit$0$19$148-$21,094
% Margin0%100%100%-6,027.9%
EBITDA-$15,844-$11,766-$18,717-$29,576
% Margin-1,584.4%-63,171.7%-12,663.2%-8,451.7%
Net Income-$16,113-$7,437-$18,833-$29,774
% Margin-1,611.3%-39,929.3%-12,741.6%-8,508.3%
EPS Diluted-3.95-11.35-145.12-1,203.05
% Growth65.2%92.2%87.9%
Operating Cash Flow-$12,827-$8,608-$21,342-$27,687
Capital Expenditures$0$0-$443-$896
Free Cash Flow-$12,827-$8,608-$21,785-$28,584
Sonnet BioTherapeutics Holdings, Inc. (SONN) Financial Statements & Key Stats | AlphaPilot